In order to use the website smoothly for you, we use cookies on the website. If you do not accept cookies, change your browser settings. By continuing to use the website, you accept the use of cookies. ALRIGHT Main navigation (without target group) Home Rare diseases Company Products Guides and brochures Links Contact information Registration is over. Additional information and questions: mail.fi@sobi.com Rare diseases Rare diseases affect small numbers of patients and are often life-threatening or cause permanent and severe harm. Rare diseases have been named between 6,000 and 8,000, but only about 400 of them have developed drug therapy that has been approved so far. Preparations Orphan drugs are part of specialty drugs and are used in the diagnosis, prevention and treatment of orphan diseases. Transparency - value transfers In June 2014, the European Pharmaceutical Advocacy Organization (EFPIA) adopted new guidelines on the disclosure of transfers of value, which have been or will be applied in all its European member associations. The guidelines require pharmaceutical companies to disclose all payments (value transfers) made to healthcare professionals (HCPs) and organizations (HCOs). Oy Swedish Orphan Biovitrum Ab mail.fi@sobi.com +358 (0) 201 558 840 Äyritie 18, FI-01510 Vantaa International contacts Footer Menu About cookies Oy Swedish Orphan Biovitrum Ab Äyritie 18, FI-01510 Vantaa